Amgen (AMGN) vs Moderna (MRNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Moderna (MRNA) has outperformed Amgen (AMGN) over the past year, gaining 605.6% versus a gain of 38.3%. Over five years, AMGN leads with a +96.0% price change compared with -39.4% for MRNA. Amgen is the larger company by market cap ($220.28 billion vs $78.65 billion), about 2.8 times the size.
Amgen pays a dividend yielding 2.41%, while Moderna does not currently pay one. Amgen converts more of its revenue into profit, with a net margin of 21.0% versus -145.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | MRNA |
|---|---|---|
| Share price | $407.44 | $197.00 |
| Market cap | $220.28B | $78.65B |
| 1-day change | -1.37% | +0.26% |
| YTD return | +24.48% | +568.02% |
| 1-year return | +38.29% | +605.59% |
| 5-year return | +96.04% | -39.40% |
| P/E ratio (TTM) | 25.31 | — |
| Forward P/E | 16.64 | — |
| EPS (TTM) | $16.10 | $-7.98 |
| Dividend yield | 2.41% | 0.00% |
| Annual dividend | $9.80 | $0.00 |
| Revenue (latest FY) | $36.75B | $1.94B |
| Revenue growth (YoY) | +9.95% | -39.93% |
| Net income (latest FY) | $7.71B | $-2.82B |
| Gross margin | 67.25% | 55.35% |
| Operating margin | 24.71% | -158.13% |
| Net margin | 20.98% | -145.16% |
| 52-week high | $447.03 | $212.22 |
| 52-week low | $288.00 | $22.28 |
| Distance from 52-week high | -8.86% | -7.17% |
| Analyst consensus | hold | hold |
| Avg. price target upside | -3.92% | -38.58% |
| Average volume | 2.73M | 17.44M |
| Shares outstanding | 540.63M | 399.24M |
| Employees | 31,500 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Amgen is about 2.8 times larger than Moderna by market value ($220.28B vs $78.65B).
- MRNA has outperformed AMGN by 567.3 percentage points over the past year.
- Amgen offers a meaningfully higher dividend yield (2.41% vs 0.00%).
- Amgen is more profitable, keeping 21.0 cents of every revenue dollar as net income versus -145.2 cents for Moderna.
- Amgen grew revenue faster in its latest fiscal year (+9.95% vs -39.93%).
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
AMGN vs MRNA FAQ
Which is bigger, Amgen or Moderna?
Amgen (AMGN) is larger, with a market capitalization of $220.28B compared with $78.65B for Moderna (MRNA).
Which stock has performed better over the past year, AMGN or MRNA?
MRNA returned +605.59% over the past 12 months, compared with +38.29% for AMGN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Amgen or Moderna?
Amgen pays a dividend yielding 2.41%, while Moderna does not currently pay a regular dividend.
Are Amgen and Moderna in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.